-
391 pharmaceutical companies posted their transcripts for the first half of the year!
Time of Update: 2021-11-05
have also reached new highs; 13 companies such as Zhifei Bio, Mindray Medical, and Hengrui Medical The profit exceeded 2 billion yuan; the gross profit margin of 18 companies including Ellis, Biotech, and Wuwu Biotech exceeded 90% .
-
The Beijing-Tianjin-Hebei "3+N" Alliance Launches the Joint Purchase of Coronary Drug Balloons and Pacemaker Medical Consumables
Time of Update: 2021-11-05
On September 8, Tianjin Medical Purchasing Center issued the "Notice on Carrying out the Joint Procurement of Coronary Drug Balloons and Pacemaker Medical Consumables in the Beijing-Tianjin-Hebei "3+N
-
Phase 3 clinical results of C3 complement inhibitors for the treatment of age-related macular degeneration released
Time of Update: 2021-11-05
On September 9, Apellis announced the top-line results obtained in two phase 3 clinical trials, DERBY and OAKS, in the research pegcetacoplan targeting the complement C3 protein .
com/news-release/2021/09/09/2294782/0/en/Apellis-Announces-Top-Line-Results-from-Phase-3-DERBY-and-OAKS-Studies-in-Geographic-Atrophy-GA -and-Plans-to-Submit-NDA-to-FDA-in-the-First-Half-of-2022.
-
Innovent announces the use of Daboshu (Xindi Lizumab injection) combined with Dayoutong (bevacizumab injection) and chemotherapy for the treatment of EGFR-mutant non-squamous non-small cell lung cancer that has failed EGFR-TKI treatment Phase III clinical study reached
Time of Update: 2021-11-05
San Francisco and Suzhou, China October 18, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the
-
JAK inhibitor gets FDA approval again to treat fatal complications of stem cell transplantation
Time of Update: 2021-11-05
Today, Incyte announced that the US FDA has approved its JAK inhibitor Jakafi (ruxolitinib) to expand its indications for the treatment of chronic graft-versus-host disease (GVHD) adults and children over 12 years old .
-
Kelun Pharmaceutical's Ceftazidime/5% Glucose Injection was approved for drug registration
Time of Update: 2021-11-05
On September 28, Kelun Pharmaceutical issued an announcement stating that its subsidiary Hunan Kelun Pharmaceutical’s chemical drug "Ceftazidime for Injection/5% Glucose Injection" has recently been approved for drug registration by the National Medical Products Administration.
-
The first domestic product! First in class small molecule MIF inhibitor application for clinical application
Time of Update: 2021-11-05
Article source: Medical Rubik's Cube InfoOn September 26, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration showed that the clinical application of Amifi Bio-targeted MIF small molecule inhibitor IPG1094 tablets was accepted by the State Food and Drug Administration .
-
Hengrui Medicine's ioverol injection passed the consistency evaluation of generic drugs
Time of Update: 2021-11-05
Ioverol injection is suitable for: 1.
Head and Enhanced CT scan of the body and excretory urography; 3.
Cardiovascular angiography, enhanced CT scan of the head and body, and excretory urography in children one year old or older .
-
Novavax submits emergency use application to WHO
Time of Update: 2021-11-05
(NASDAQ: NVAX), a biotechnology company dedicated to the development and commercialization of next-generation vaccines for severe infectious diseases, cooperates with it Partner Serum Institute of India Private Limited (SII) announced today that the two companies have submitted relevant regulatory documents to the World Health Organization (WHO) to apply for Novavax recombinant nanoparticle protein new coronary pneumonia vaccine candidates using Matrix-M™ adjuvant.
-
This biosimilar approval document is worth 175 million yuan
Time of Update: 2021-11-05
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn September 28, the official website of the State Food and Drug Administration showed that the marketing application of Hisun Pharmaceutical's infliximab biosimilar was officially approved by the NMPA .
-
National Cheng Kung University finally clears customs
Time of Update: 2021-11-05
In the announcement, the China Securities Regulatory Commission announced that it agreed to the registration of the initial public offering of shares on the National Cheng Kung University Biotech Innovation Board in accordance with legal procedures, and stated that relevant companies and their underwriters will negotiate with the Shanghai Stock Exchange to determine the issuance schedule and publish prospectus documents one after another .
-
Promote "what can be done" and crack the "can't be done" where does confidence in Chinese medicine come from
Time of Update: 2021-11-05
In the inheritance and development of more than two thousand years, traditional Chinese medicine has created world-renowned achievements, formed a systematic and complete scientific theory, and establ
-
Eisai/Bojian AD antibody therapy lecanemab begins to submit rolling marketing application to FDA
Time of Update: 2021-11-05
On September 27, Eisai announced that it has begun rolling submissions to the US FDA through the accelerated approval channel for its research Alzheimer's disease (AD) antibody therapy lecanemab biological product license application (BLA) for early treatment AD .
-
Novo Nordisk reached a settlement for $100 million in shareholder class action insulin pricing opaque
Time of Update: 2021-11-05
CompilationAspirinOn September 24, 2021, in a 2017 lawsuit filed in the Federal District Court of New Jersey after shareholders claimed that the insulin pricing disclosed by them was opaque, Novo Nordisk agreed to pay the plaintiff a settlement agreement of US$100 million .
-
Fuhong Henlius successfully concluded the 2021 Service and Trade Fair
Time of Update: 2021-11-05
Among Chinese pharmaceutical companies, as a representative of a number of innovations that have been harvested after only 11 years of establishment, Henlius is considered young; and the innate intern
-
Progress in the treatment of pancreatic cancer: PD-1 antibody + Pin1 inhibitor + gemcitabine can eliminate tumors in mice
Time of Update: 2021-11-05
Pin1 is overexpressed in human PDAC cancer cells and CAF, and is closely related to the promotion of connective tissue proliferation, immunosuppressive TME, and poor patient survival .
-
Chuangxiang Biotechnology completes the first patient's first dosing for the global Phase 2 clinical study in the U.S.
Time of Update: 2021-11-05
Chuangxiang Bio announced that the global phase 2 clinical study ASPIRE, which aims to evaluate the efficacy of izokibep in the treatment of ankylosing spondylitis, completed the first administration of the first patient in California on August 25, Beijing time.
-
Is it difficult for manufacturers of Chinese medicinal materials to increase prices?
Time of Update: 2021-11-05
However, due to the closure of villages and roads in many Chinese medicinal materials production areas during the epidemic period, transportation was blocked, causing the market to bottom out or out of stalls, and the prices of some varieties still rose .
-
Check more!
Time of Update: 2021-11-05
At the same time that the pharmacy cleaned up the windows and advertisements on the exterior wall, the law enforcement team also issued a "Notice of Ordering Correction" to its operators, requesting them to rectify the existing problems immediately, and no relevant violations should occur again .
-
Huibaoyuan Bio's new anti-cancer drug xylazine obtained clinical trial approval from the U.S. FDA
Time of Update: 2021-11-05
This study aims to evaluate the overall survival benefit and safety of JP001 combined with standard radiotherapy and chemotherapy for newly diagnosed GBM patients .
Combined with surgical resection and radiotherapy, the median survival can be extended to 12.
